Vanda Pharmaceuticals Inc. (0LKB.L)

4,8200 +0,0585 (+1,23%) Alla chiusura: 06:40PM BST

Vanda Pharmaceuticals Inc.

2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
202 734 3400
https://www.vandapharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 203

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Mihael H. Polymeropoulos M.D.	Founder, President, CEO & Chairman of The Board	1,92M	N/D	1960
Mr. Timothy Williams	Senior VP, General Counsel & Secretary	890,65k	N/D	1976
Mr. Joakim Wijkstrom	Senior VP & Chief Marketing Officer	846,33k	N/D	1966
Mr. Scott L. Howell	Chief People Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Governance aziendale

L'ISS Governance QualityScore di Vanda Pharmaceuticals Inc. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 6; diritti degli azionisti: 5; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.